• Home

• Small Molecules: Hit identification

• Small Molecules: Hit-to-Lead optimization

• Small Molecules: physicochemical properties

• Small Molecules: ADME

• Small Molecules: Toxicity

• Small Molecules: Selectivity

• Antibodies: Humanization and Optimization

• Protein Modeling. Discovery

• Protein Modeling: HERG binding

• Protein Modeling: Albumin binding

• Quantum Discussions Forum    

You access the old version of our website. Please point your browser to our new home page.
English, Français

Download Free Trial beta-version of Quantum 3.3!

Try the latest QUANTUM docking/library screening software for FREE. Fill in your email address in the form below to get a download link (it may take up to several minutes to download next page!!):

Please, send me a link to Quantum 3.3.0 trial version. My e-mail:

A short docking guide is here.

The software description and a summary of the key capabilities is available here.

Grab this presentation to see how QUANTUM software can be used to rediscover blockbuster drugs.

The latest general overveiw of Quantum Pharmaceuticals products and services can be downloaded here.

The latest from our Blog: Docking selectivity: Additive vs. non-additive force field


We accept questions, suggestions, feature requests and bug reports at our QUANTUM software forum

ICQ consultant

Quantum Pharmaceuticals, the leader in drug discovery technology, serves the life sciences industry and research community by providing flexible molecular docking software, compound profiling and selectivity testing services , virtual screening services and other top-of-the-line computational chemistry and computer aided drug design products and contract research services

The Quantum computer aided drug design and computational chemistry technology was developed using a new paradigm in molecular modeling – applying quantum and molecular physics instead of statistical scoring-function-like and QSAR-like methods.

The proprietary molecular simulation and molecular dynamics technology includes the latest achievements in the fields of chemistry, physics and mathematics. It demonstrates outstanding speed and accuracy of affinity calculations due to fast quantum calculations, which take into account full flexibility of molecules, solvation effects, and entropy contribution. This provides unprecedented possibilities for in-silico drug discovery and gives insight into ligand-receptor, protein-protein and other molecular interactions.

Quantum Pharmaceuticals’ Computer Aided Drug Design technology has made it possible to create disease target focused compound Q-Lead Libraries, a revolutionary product for the biotechnology and pharmaceutical industry. The targeted libraries of in-silico discovered inhibitors dramatically reduce time of early drug discovery.

Quantum’s proprietary molecular modeling technology platform is succesfuly used in collaborative and in-house Quantum Pharmaceuticals’ drug discovery projects to discover drug candidates for different diseases including AIDS, TB, Alzheimer’s disease, COPD and others, as well as for compound selectivity and proteomics studies.